RecruitingFocal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Eligible age
18–75 yrs
Accepts
All genders
Locations
26 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Sponsor: Biohaven Therapeutics Ltd.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06132893 · last updated 2026-08-24